jaktinib
Small moleculeexperimental
Clinical trial activity
37 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
30
Phase 3
7
Phase 4
0
Earliest trial started Sep 28, 2017 (NCT03314402)
Timeline
Indications
Studied for
- Alopecia Areata · Phase 3
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- COVID-19 · Phase 2
- Dermatitis, Atopic · Phase 3
- Graft vs Host Disease · Phase 2
- Healthy Volunteers · Phase 1
- Hepatic Insufficiency · Phase 1
- Idiopathic Pulmonary Fibrosis · Phase 2
- Lymphoma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Pneumonia · Phase 2
- Polycythemia Vera · Phase 2
- Primary Myelofibrosis · Phase 3
- Psoriasis · Phase 2
- Spondylitis, Ankylosing · Phase 3
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07285889 | Phase 1/Phase 2 (Phase 2) | Dec 3, 2025 | Zhejiang University |
| NCT07197112 | Phase 2 | Oct 1, 2025 | Jiao Tong University |
| NCT07185633 | Phase 2 | Oct 1, 2025 | Soochow University |
| NCT07142837 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2025 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT07157306 | Phase 2 | Sep 10, 2025 | Tianjin Medical University |
| NCT07080216 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2025 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT07012304 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | Peking University |
| NCT06883526 | Phase 1/Phase 2 (Phase 2) | May 31, 2025 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT06903377 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05861128 | Phase 3 | Jun 30, 2024 | Jiao Tong University, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05688839 | Phase 2 | Apr 30, 2024 | Changsha Taihe Hospital, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05686629 | Phase 2 | Apr 30, 2024 | Sichuan University, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT06193148 | Phase 1 | Mar 18, 2024 | Soochow University, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05702788 | Phase 2 | Dec 31, 2023 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT06132243 | Phase 1 | Nov 30, 2023 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05861102 | Phase 3 | Jul 20, 2023 | Jiao Tong University, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05672888 | Phase 2 | Mar 31, 2023 | Zhejiang University |
| NCT05676242 | Phase 3 | Jan 11, 2023 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05279001 | Phase 1 | Jul 1, 2022 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT05526222 | Phase 3 | Jul 1, 2022 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
Showing 20 of 37 trials
Page 1 / 2
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | For profit | 31 | 31 | 3 | 2017 |
| Zhejiang University | Academic/Hospital | 6 | 2 | 2 | 2018 |
| Jiao Tong University | Academic/Hospital | 4 | 1 | 2 | 2020 |
| Soochow University | Academic/Hospital | 4 | 1 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 0 | 2 | 2020 |
| Peking University | Academic/Hospital | 3 | 1 | 2 | 2021 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Changsha Taihe Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Tianjin Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
13 organizations
Page 1 / 1